Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 344 publications

Retraction Note: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.

Retraction Note: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.

Journal: Journal of cancer research and clinical oncology
Published: October 21, 2025

Proteome-wide multi-trait association analyses prioritize candidate proteins and therapeutic targets for psychiatric disorders.

Proteome-wide multi-trait association analyses prioritize candidate proteins and therapeutic targets for psychiatric disorders.

Journal: Journal of affective disorders
Published: August 22, 2025

Repurposing immunomodulatory drugs targeting microglia for amyotrophic lateral sclerosis.

Repurposing immunomodulatory drugs targeting microglia for amyotrophic lateral sclerosis.

Journal: Brain research
Published: June 25, 2025

Protein domain movement involved in binding of belinostat and HPOB as inhibitors of histone deacetylase 6 (HDAC6): a hybrid automated-interactive docking study.

Protein domain movement involved in binding of belinostat and HPOB as inhibitors of histone deacetylase 6 (HDAC6): a hybrid automated-interactive docking study.

Journal: Journal of computer-aided molecular design
Published: May 28, 2025

EXPRESSION OF CONCERN: Growth Inhibition of Pancreatic Cancer Cells by Histone Deacetylase Inhibitor Belinostat Through Suppression of Multiple Pathways Including Hif, Nfkb, and Mtor Signaling In Vitro and In Vivo.

EXPRESSION OF CONCERN: Growth Inhibition of Pancreatic Cancer Cells by Histone Deacetylase Inhibitor Belinostat Through Suppression of Multiple Pathways Including Hif, Nfkb, and Mtor Signaling In Vitro and In Vivo.

Journal: Molecular carcinogenesis
Published: May 26, 2025

CREB binding protein (CREBBP): Structure-based perspectives for the development of clinical inhibitors.

CREB binding protein (CREBBP): Structure-based perspectives for the development of clinical inhibitors.

Journal: Translational oncology
Published: May 20, 2025

Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas.

Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas.

Journal: JCI insight
Published: May 12, 2025

Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.

Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.

Journal: British journal of haematology
Published: April 11, 2025

PLEKHG7 Expression: A Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma.

PLEKHG7 Expression: A Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma.

Journal: Protein and peptide letters
Published: April 10, 2025

Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization.

Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization.

Journal: Advanced materials (Deerfield Beach, Fla.)
Published: March 28, 2025

Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma.

Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma.

Journal: iScience
Published: March 25, 2025

Adverse drug reaction profiles of histone deacetylase inhibitors.

Adverse drug reaction profiles of histone deacetylase inhibitors.

Journal: Scientific reports
Published: March 17, 2025
Showing 1-12 of 344

Last Updated: 01/07/2026